Feedback / Questions
Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca
DS-8201: "Median time to response was 1.6 months (95% CI, 1.4-2.6 months)"; Breast cancer
(Daiichi Sankyo)
-
Dec 18, 2019 -
R&D Day 2019: "Confirmed ORR: 60.9%a (95% CI, 53.4%–68.0%) 11 CRs"
P2 data
https://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005462/R&D%20Day%202019_E.pdf
Dec 18, 2019
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious